Company intelligence / Profile preview

Evalve

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Evalve's MitraClip device received CE Mark and launched commercial sales in Europe in 2008, offering the first less invasive, catheter-based therapy for mitral regurgitation. Clinical evaluation in the US (EVEREST study) was ongoing at time of Abbott's acquisition. Early results showed effective MR reduction and improved patient symptoms with reduced recovery time compared to open-heart surgery.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

The Foundry (incubator)

Beyond the preview

Go deeper on Evalve.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evalve.

Explore the full profile